Diffusion restriction as a predictor of response in recurrent glioblastoma patients receiving bevacizumab.

2024 Background: Bevacizumab (BEV) improves outcome in a subset of patients with recurrent glioblastoma (GBM). Identification of this subset would improve patient selection for BEV therapy. The obs...